Episode 218: Statin Therapy Fundamentals

Episode 218: Statin Therapy Fundamentals

Author: Rio Bravo Family Medicine Residency Program April 6, 2026 Duration: 17:12

Episode 218: Statin Therapy Fundamentals

What are statins?

Zohal: Statins are medications that lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which prevents cholesterol synthesis in the liver. By doing so, statins decrease low-density lipoprotein cholesterol (LDL-C). 

Why should we lower LDL?

Zohal: There are four main lipoproteins that transport fats in blood, including chylomicrons, VLDL, LDL, and HDL. This is where we get our “bad cholesterol” vs. “good cholesterol”. Of these, LDL is most associated with an increased risk in cardiovascular disease, while a higher HDL is associated with lower risk. Thus, reducing LDL subsequently reduces the risk of cardiovascular disease. 

Arreaza: The lowest LDL I’ve seen was 25, and the highest HDL was 60. HDL doesn’t really have a strict upper limit, but most people fall between 40 and 60. Extremely high HDL—above 100—may not always be protective and can sometimes signal underlying issues.

Zohal: My HDL is 70! Statins are used for both primary prevention, meaning preventing cardiovascular disease before it occurs, and secondary prevention, meaning preventing disease progression in patients who already have cardiovascular disease.

History of statins.

Zohal: In the early 1900’s, researchers were studying the association between cholesterol and atherosclerosis, and at that time, they primarily used animal subjects. These studies were initially not taken seriously, because most believed cardiovascular disease in humans were simply due to aging and was not preventable. 

It wasn’t until the middle of the century when researchers began observing that increased levels of LDL and decreased HDL was correlated with an increased rate of heart attacks. This finding prompted interest in determining the pathway of cholesterol synthesis in the human body. 

Statins were first discovered in the 1970s when researchers identified compounds that inhibit a critical step in cholesterol synthesis. The first statin approved for clinical use was Lovastatin in 1987.

Since then, multiple statins have been developed, including Atorvastatin, Rosuvastatin, Simvastatin, and Pravastatin. Further clinical trials in the 1990s and 2000s showed that statins significantly reduce myocardial infarction, stroke, and cardiovascular mortality.

Why do Statins Matter in Primary Prevention

Zohal: Cardiovascular disease is the most common cause of death worldwide. As previously mentioned, elevated LDL cholesterol contributes to the development of atherosclerotic plaques within arteries, which can lead to heart attack and stroke. By lowering LDL cholesterol and stabilizing plaque formation, statins implemented in a timely manner significantly reduce the risk of atherosclerotic cardiovascular disease.

Arreaza: One of the things I love most about primary care is prevention. You’re working upstream, often quietly, humbly, helping people avoid disease before it starts. And the truth is—you rarely see the full impact of your actions. You don’t get a notification that says, “this patient didn’t have a heart attack because of you.” But every time you help someone control their blood pressure, quit smoking, improve their diet, or stay consistent with their medications, you’re shifting their tracks. You’re reducing risk in ways that may never be fully visible. That’s the paradox and the beauty of it: in primary care, your highest victories are often events that never happen. 

Who Should Receive Statins for Primary Prevention?

Zohal: Recommendations slightly differ depending on who you ask. We look to the U.S. Preventive Services Task Force, the American College of Cardiology, and the American Heart Association for their recommendations regarding statins for primary prevention.

USPSTF on statins.

The U.S. Preventive Services Task Force (or USPSTF for short) is an organization that works to improve the health of people nationwide by making evidence-based recommendations on effective ways to prevent disease & prolong life. They recommend statins for the primary prevention of cardiovascular disease in:

  • Adults 40–75 years old
  • With one or more cardiovascular risk factors such as dyslipidemia, diabetes, hypertension, or smoking
  • AND a 10-year cardiovascular risk of 10% or greater

Their recommendations are graded A, B, C, D, and I, depending on the strength of evidence and this is a Grade B recommendation.

Arreaza: So, you have to meet all the criteria to receive a statin, according to USPSTF: 40-75, one CV risk factor and a high 10-y ASCVD score, by the way, the ASCVD risk calculator was introduced in 2013 by AHA/ACC. It is available online for free and many EHRs have integrated this tool into their software. For example, if you use EPIC, you can type .ascvd and get a score automatically. What about patients with a cardiovascular risk less than 10%?

Zohal: For patients with a 7.5–10% risk, some may offer statin therapy on a case-by-case basis as this is a Grade C recommendation. But I’ll get more into this later.

Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! 

_____________________

References:

  1. Grundy SM, et.al, Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10. Erratum in: Circulation. 2019 Jun 18;139(25):e1182-e1186. doi: 10.1161/CIR.0000000000000698. Erratum in: Circulation. 2023 Aug 15;148(7):e5. doi: 10.1161/CIR.0000000000001172. PMID: 30586774; PMCID: PMC7403606. https://pubmed.ncbi.nlm.nih.gov/30586774/
  2. U.S. Preventive Services Task Force. (2022, August 23). Statin use for the primary prevention of cardiovascular disease in adults: Preventive medication.
    https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medicatio
  3. American College of Cardiology ASCVD Risk Estimator: https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/
  4. Guideline Central. (2026, March). ACC/AHA dyslipidemia guideline spotlight (March 2026).
    https://www.guidelinecentral.com/insights/mar-2026-accaha-dyslipidemia-guideline-spotlight/
  5. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484-93. doi: 10.2183/pjab.86.484. PMID: 20467214; PMCID: PMC3108295. https://pubmed.ncbi.nlm.nih.gov/20467214/
  6. Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Tune into Rio Bravo qWeek for a genuine look inside the daily life and learning of a family medicine residency. Produced by the Rio Bravo Family Medicine Residency Program, this podcast brings you the voices of the residents and faculty themselves as they navigate the vast world of primary care. Each episode focuses on key medical topics and relevant clinical discussions, drawn directly from their training and experiences. What sets this series apart is its authentic tone-conversations here are often lightened with medical humor and peppered with practical Spanish medical terminology, reflecting the real-world needs of a diverse patient population. It’s a unique blend of solid education and relatable shop talk, offering insights for medical students, healthcare professionals, or anyone curious about the human side of medicine. You’ll find this podcast to be more than a lecture; it’s a window into the collaborative and ever-evolving journey of becoming a family physician.
Author: Language: English Episodes: 218

Rio Bravo qWeek
Podcast Episodes
Episode 67 - Covid, Food, and HIV [not-audio_url] [/not-audio_url]

Duration: 19:03
Episode 67: Covid, Food, and HIV. Medical students discuss the relationship between high cholesterol and COVID-19, the effect of food order in postprandial glucose and insulin, and HIV history. Moderated by Hector Arreaz…
Episode 66 - Meth Abuse [not-audio_url] [/not-audio_url]

Duration: 29:55
Episode 66: Meth Abuse. By Ikenna Nwosu, MD, and Hector Arreaza, MD. Discussion about screening, epidemiology, clinical presentation, diagnosis, and treatment of meth abuse. Association between intranasal corticosteroids…
Episode 65 - Delta Variant [not-audio_url] [/not-audio_url]

Duration: 19:06
Episode 65: Delta Variant. Harendra and Dr Arreaza present current evidence regarding the delta variant of SARS-CoV-2 (COVID-19), effectiveness of vaccines, and more. Introduction: Booster shots for the COVID-19 vaccine.…
Episode 64 - H. pylori [not-audio_url] [/not-audio_url]

Duration: 20:56
Episode 64: H. pylori. Dr Lorenzo explains testing, diagnosis, and treatments for H. pylori, a bacterium that can cause peptic ulcer disease and other complications.By Anabell Lorenzo, MD, and Hector Arreaza, MD. This is…
Episode 63 - Tumor Markers Basics [not-audio_url] [/not-audio_url]

Duration: 29:17
Episode 63: Tumor Markers Basics. George and Harendra discuss with Dr Arreaza the role of tumor markers in the diagnosis and monitoring of different types of cancer. Introduction: Recent News about COVID-19Written by Hec…
Episode 62 - Onychomycosis [not-audio_url] [/not-audio_url]

Duration: 16:07
Episode 62: Onychomycosis (nail fungus). Future doctors Gabrielle and Jeanette discuss with Dr Arreaza the diagnosis and treatment of onychomycosis, AKA nail fungus.By Gabrielle Robinson, MS3, and Jeanette Adereti, MS3Ro…
Episode 61 - Semaglutide for Obesity [not-audio_url] [/not-audio_url]

Duration: 14:25
Episode 61: Semaglutide for Obesity. Dr Arreaza discusses with Dr Carranza the results of the STEP trials: Semaglutide Treatment Effect in People with obesity, which allowed semaglutide gain FDA approval as a treatment f…
Episode 60 - Variety of Topics [not-audio_url] [/not-audio_url]

Duration: 11:50
Episode 60: Variety of Topics. Gabrielle Robinson (MS3) discusses with Dr Arreaza these topics: IsoPSA, 3HP for LTBI, shingles vaccine, and DELC.Introduction: You will hear a conversation between Gabrielle Robinson, a 3r…
Episode 59 - The Keto Diet [not-audio_url] [/not-audio_url]

Duration: 33:14
Episode 59: What is Keto? Discussion about the benefits and risks of the keto diet. Introduction about the CDC Contraceptive app.Introduction: Contraception App Update (CDC)By Cecilia Covenas, MD, and Hector Arreaza, MDT…
Episode 58 - Transaminitis [not-audio_url] [/not-audio_url]

Duration: 30:43
Episode 58: Transaminitis. Elevated aminotransferases can be caused by intrahepatic and extrahepatic causes, Dr Martinez and Dr Civelli explain the workup of transaminitis, distribution of Chantix was stopped by Pfizer,…